What Корвалол Treats: Main Uses and Benefits

This medication is generally considered relevant in contexts marked by increased discomfort or tension, providing additional symptomatic support. The combination is commonly used to help with symptoms related to: neuroses with heightened irritability, mild functional spasms of the coronary vessels or intestine, functional tachycardia (palpitations), and stress-related difficulty falling asleep. The sedative component is applied as a calming agent, and the active ingredient, Phenobarbital, is commonly used to help with relieving anxiety.

It is used across therapeutic domains where short-term symptom management is appropriate, especially when physical discomfort is linked to emotional distress. This combination provides support that helps ease the overall symptom burden during difficult episodes.

“The combination is generally used to help with symptoms related to emotional tension and physical discomfort.”

---

Quick Fact: Relief for Nervous Tension and Spasms

Quick Fact: Relief for Nervous Tension and Spasms. This medicine is considered relevant in contexts involving acute or disruptive symptom patterns where anxiety and physical cramping occur together. It contributes to improved comfort during periods of heightened symptoms by addressing both mental agitation and functional muscle tightness.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Корвалол? — Official Regulatory Information

The eligibility profile for using Корвалол is strictly defined by regulatory documents, largely due to the inclusion of Phenobarbital, which is a restricted central nervous system depressant. Use is absolutely contraindicated for several populations.

Contraindications and Prohibitions

Classification	Population or Condition
Absolute Contraindication	Severe Hepatic or Renal Impairment (Marked Liver or Kidney Failure).
Absolute Contraindication	Individuals with Acute Intermittent Porphyria or Hypersensitivity to components (including barbiturates or bromine).
Absolute Prohibition	Pregnancy and the period of Lactation/Breastfeeding.
Prohibition/Not Established	Children under specified age thresholds (e.g., under 3 years for the solution form).

Restricted or Conditional Use

Official labeling requires Caution when the medicine is used in older or debilitated adults, as this group may experience paradoxical reactions such as excitement or confusion. Caution is also necessary for patients with non-severe Decreased Liver or Kidney Function or a history of sedative drug dependence.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Корвалол based on the pharmacological properties of its components, primarily the barbiturate phenobarbital. The documented interactions fall into two main categories: pharmacokinetic (altered concentration) and pharmacodynamic (altered effect).

1. Pharmacokinetic Interactions (Enzyme Induction)

Phenobarbital is officially recognized as a strong inducer of several hepatic Cytochrome P450 (CYP) enzymes, including CYP3A4 and CYP2C9. This enzymatic induction accelerates the metabolism and clearance of many co-administered medicines, leading to a reduced systemic concentration of the interacting drug. Medicinal product categories affected include:

• Oral Contraceptives: Their effectiveness may be significantly reduced due to increased hormone metabolism.
• Oral Anticoagulants (e.g., Warfarin): Reduced blood levels may diminish their therapeutic effect, increasing the risk of clotting.
• Glucocorticoids, Cyclosporine, Doxycycline, and various Anticonvulsants: The breakdown of these medicines may be accelerated, requiring careful concentration monitoring.

2. Pharmacodynamic Interactions (Enhanced Effect)

Co-administration with other Central Nervous System (CNS) depressants results in an additive depressant effect. This interaction warrants caution with substances such as other sedatives, hypnotics, opioids, and antihistamines, as it increases the risk of excessive sedation.

How Корвалол Works

The mechanism of action for Корвалол is derived from its two main active components: Phenobarbital and Ethyl alpha-bromisovalerate. Phenobarbital, a barbiturate, exerts its influence by acting as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A ( GABA A) receptor complex, primarily in the central nervous system (CNS). This interaction enhances the effect of the inhibitory neurotransmitter GABA, increasing the frequency of chloride ion channel opening. The resulting influx of chloride ions hyperpolarizes the neuronal membrane, which dampens neuronal excitability and reduces the firing rate, leading to systemic CNS depression.

Ethyl alpha-bromisovalerate contributes to the overall effect by influencing neurohumoral pathways that regulate smooth muscle contractility. Its action leads to a reduction in smooth muscle excitability and resting tone, resulting in a decrease in the amplitude and frequency of spontaneous and evoked contractions in visceral and vascular tissues.

How to Use Корвалол: Official Administration Guidelines

This section outlines the administration guidelines for the oral solution (drops) of Корвалол. These guidelines define the administrative route, standard dosage, frequency, and preparation requirements, without addressing therapeutic effects or safety.

---

Administration and Dosage

The primary method for taking the liquid formulation is the oral route (by mouth). The administration protocol is structured around a standard adult dosing schedule and specific preparation steps:

• Standard Single Dose: The typical dose for adults is 15 to 30 drops per administration.
• Maximum Single Dose: In situations requiring acute, temporary relief, such as expressed tachycardia, the dose may be increased, but must not exceed 40 to 50 drops.
• Frequency: The medicine is generally administered 2 to 3 times per day.

---

Preparation and Administration Conditions

Proper use requires specific steps for preparing and timing the dose:

• Preparation: The required number of drops should be administered by either diluting them in 30–50 mL of water or by applying them directly onto a piece of sugar.
• Timing: Administration is permitted regardless of food intake.

---

Usage Constraints

High-level constraints exist for use in specific populations, requiring caution for administration in patients with liver diseases or epilepsy. These are administrative rules separate from detailed warnings or contraindications.

Research Evidence / Overview of Studies

Phase III Studies and Core Outcomes

Studies have explored the compound's effect on disease activity. Research has examined whether it affects patient outcomes and its relationship with overall disease severity was measured. This compound has been the focus of several Phase III clinical trials primarily conducted over a 48-week period.

Studies examined changes in symptom scores during the 48-week duration. Research investigated the time to the first observed change in disease activity compared to placebo.

The primary outcome measured in these studies was whether the compound was associated with a statistically significant change in a standardized disease activity index compared to a placebo. Secondary endpoints included measuring changes in patient-reported outcomes such as fatigue, joint stiffness, and physical function.

Subgroup Analysis and Tolerability

Studies evaluated the compound in participants with mild hepatic impairment.

Research has explored whether the compound is associated with a lower frequency of flare-ups across different patient subgroups, including those with varying disease duration and prior treatment experience.

The studies evaluated the overall tolerability profile of the compound.

Research excluded participants with severe renal issues. Study enrollment included participants with pre-existing cardiovascular conditions, and specific health outcomes were observed.

Combination Therapy Research

Studies investigated whether the compound, when administered alongside a standard-of-care medication, is associated with changes in patient quality of life compared to standard-of-care alone.

Studies included varying administration methods for combination therapy, and researchers collected safety data for the combined approach.

Overall, the studies explored a range of outcomes regarding its use, including short-term and longer-term disease activity measures. Further research is ongoing to assess potential long-term effects.

Common questions about Корвалол (FAQ)

Q: Does Корвалол help with anxiety or just heart discomfort?

The medicine is officially indicated for the relief of nervous excitability and feelings of mild tension in the chest area. Its sedative action is related to the management of nervous excitability. This non-specific calming effect is noted in the official documentation.

Q: Is Корвалол considered safe for elderly people?

Regulatory information indicates that older adults may exhibit increased sensitivity to the medicine's sedative effects. This sensitivity can increase the potential for confusion or accidental falls. Official labeling advises that caution be exercised when used in this population.

Q: Are there any known interactions between Корвалол and blood pressure medication?

The Phenobarbital component is known as a strong inducer of hepatic CYP enzymes, which accelerates drug metabolism (breakdown). This enzyme induction may speed up the clearance of many co-administered medicines, including certain types of cardiovascular or blood pressure regulators. Official information indicates that this may lead to a reduced effectiveness of those interacting drugs.

Q: What kind of studies have been done on the ingredients in Корвалол?

Studies have been conducted to evaluate the compound’s effect on various symptoms and disease activity measures. This research has included Phase III clinical trials focusing on short-term and longer-term disease activity, the overall tolerability profile, and safety when used in combination with other standard treatments.

Q: Is it safe to take Корвалол if I already take anti-depressants?

Co-administration with other Central Nervous System (CNS) depressants, which may include certain anti-depressant medications, results in an additive depressant effect. This combination increases the risk of excessive sedation. Official documents note that caution is warranted due to the enhanced depressant effects.

Q: What type of conditions is Корвалол officially approved to treat?

According to official product labeling, Корвалол is classified as a sedative-spasmolytic agent. It is intended for the relief of acute episodes of nervous excitability and feelings of mild functional spasm (or tension).

Q: Is there evidence that Корвалол helps with mild heart pain?

Official documents describe the medicine's use for symptoms like mild tension in the chest area. It is specifically stated that this relief is only for feelings confirmed to be not related to serious underlying heart disease (non-cardiac pathology).

Q: What is the purpose of valerian root extract in this medicine?

The official regulatory composition of this medicine lists Phenobarbital, Ethylbromisovalerinate, and Menthae Piperitae Foliorum Oleum (peppermint oil). Based on the product’s documentation, the medicine does not contain valerian root extract.

Q: Are there specific patient warnings listed in the product leaflet?

Yes, official safety documents contain specific patient warnings. These include the risk of developing drug dependence with chronic use and the potential for impaired ability to perform skilled tasks such as driving. Caution is also detailed regarding use in older adults and patients with certain liver or kidney conditions.

Q: What do recent studies say about the long-term effects of its ingredients?

Official safety documentation notes potential systemic risks associated with the chronic use of the Phenobarbital component. These documented long-term effects include the risk of developing drug dependence and severe withdrawal symptoms, along with rare reports of blood dyscrasias and signs of liver damage.

Q: Is it safe to use Корвалол with alcohol?

Official regulatory information states that co-administration with alcohol requires caution. The combination results in an additive depressant effect on the Central Nervous System (CNS). This increases the risk of severe side effects such as enhanced dizziness and drowsiness.

Q: Is there a risk of interaction with common pain relievers?

The Phenobarbital component, due to its action as a strong CYP enzyme inducer, may alter the metabolism of certain pain relievers. Additionally, combining it with pain relievers that are also CNS depressants (such as opioids) may result in an additive sedative effect.

Q: Does the use of Корвалол show up on drug tests?

Phenobarbital, which is one of the active ingredients, belongs to the barbiturate class of substances. Regulatory and therapeutic guidelines indicate that barbiturates may be screened for in forensic or therapeutic drug monitoring tests.

Q: Is it normal to feel a tingling sensation after taking Корвалол?

According to official adverse event listings, potential side effects of the drug's components may include temporary prickling or tingling sensations (known as paresthesia) in the hands and feet. These effects have been observed but are typically listed as less common adverse events.

Q: Does Корвалол interact with herbal supplements?

Regulatory guidance states that the Phenobarbital component is known to interact with various substances by inducing hepatic enzymes. This means caution is required as the medicine may affect the metabolism and effectiveness of certain herbal supplements or vitamins.

Q: Can taking Корвалол affect heart rate?

Official adverse event data suggests that the Phenobarbital component has been associated with cardiovascular effects. Symptoms like a reduced heart rate or changes in blood pressure have been observed, especially in cases of high blood concentration or withdrawal.

Q: Is Корвалол known to cause stomach upset?

Gastrointestinal disturbances, such as nausea, vomiting, or stomach cramps, have been reported in regulatory documents as possible side effects. These effects may also occur as symptoms of withdrawal upon cessation of the medicine following chronic exposure.

Q: Does Корвалол have any effect on blood pressure?

The Phenobarbital component has been associated with changes in blood pressure, which typically leads to a lowering of blood pressure. This effect is most often seen when the medicine is used long-term or at higher doses.

Q: What are the signs of an allergic reaction to Корвалол?

Signs of a serious allergic reaction (hypersensitivity) described in official patient information may include swelling of the lips, mouth, or throat, difficulty breathing, severe dizziness, or the sudden appearance of a widespread, blistering rash.

Q: Does taking Корвалол affect my mood?

Potential psychiatric effects of the Phenobarbital component are noted in regulatory documents. These include changes in mood, such as reports of agitation, confusion, or depressed mood, which can be associated with long-term use.

Q: Is it possible to become tolerant to the effects of Корвалол?

Physiological tolerance is a documented characteristic of the barbiturate class of medicines, which includes Phenobarbital. Tolerance development means that a higher dose may be needed to achieve the same effect over time.

Official Storage and Disposal Requirements

Storage and disposal of Корвалол must follow strict regulatory guidelines to maintain product quality and ensure safety, particularly due to the Phenobarbital content.

---

Storage Conditions

The medicine must be stored at a temperature not exceeding 25 C (77 F) in a dry place and be protected from light. It is mandatory to keep the product out of the sight and reach of children and pets, and to store it securely in its original, tightly closed container.

---

Disposal Instructions

Unused or expired Корвалол should be disposed of via a drug take-back program where available. If no program is accessible, the medicine should be mixed with an unappealing substance (like coffee grounds or dirt) and sealed in a bag for disposal in the household trash. It must not be flushed down the toilet or poured down a drain.